# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number: K073042 B. Purpose for Submission:

To seek clearance for modification to the Indications for Use of the HemosIL D-Dimer to include an exclusionary claim for deep venous thromboembolism and pulmonary embolism

# C. Measurand:

# E. Applicant:

# G. Regulatory Information:

1. Regulation section: 864.7320

2. Classification: II

3. Product code: DAP

4. Panel: 81 Hematology

# H. Intended Use:

1. Intended use(s):

HemosIL D-Dimer is an automated latex enhanced immunoassay for the quantitative determination of D-Dimer in human citrated plasma on IL Coagulation Systems.

2. Indication(s) for use:

HemosIL D-Dimer is used in conjunction with a clinical pretest probability (PTP) assessment model to exclude venous thromboembolism (VTE) in outpatients suspected of deep venous thrombosis (DVT) and pulmonary embolism (PE).

3. Special conditions for use statement(s): N/A

4. Special instrument requirements: IL Coagulation Systems

# I. Device Description:

The HemosIL D-Dimer assay is a quantitative test for the turbidimetric immunoassay determination of fibrin degradation products in citrated plasma. The HemosIL D-Dimer test kit consists of latex reagent, reaction buffer, and D-Dimer calibrator. The latex reagent contains latex particles coated with a monoclonal antibody which is highly specific for the D-Dimer domain included in fibrin soluble derivatives.

# J. Substantial Equivalence Information:

1. Predicate device name(s): HemosIL D-Dimer HS   
2. Predicate 510(k) number(s): K070927   
3. Comparison with predicate:

<table><tr><td colspan="3">Similarities</td></tr><tr><td>Item</td><td>Modified Device: HemosIL D-Dimer</td><td>Predicate Device: HemosIL D-Dimer HS (K070927)</td></tr><tr><td>Indications for Use</td><td>Same as K070927</td><td>For use in conjunction with a clinical pretest probability (PTP) assessment model to exclude venous thromboembolism (VTE) in outpatients suspected of deep venous thromboembolism (DVT) and pulmonary</td></tr><tr><td>Assay principle</td><td>Same as K070927</td><td>embolism (PE). Latex-enhanced immunoturbidmetric assay</td></tr><tr><td>Sample</td><td>Same as K070927</td><td>Citrated plasma</td></tr><tr><td>Clinical Cut-off</td><td>Same as K070927</td><td>230 ng/mL</td></tr><tr><td colspan="3"></td></tr><tr><td></td><td>Differences</td><td>Predicate Device:</td></tr><tr><td>Item</td><td>Modified Device: HemosIL D-Dimer</td><td>HemosIL D-Dimer HS (K070927)</td></tr><tr><td>Instrument</td><td>IL Coagulation Systems</td><td>ACL TOP only</td></tr><tr><td>Measuring Range</td><td>200 - 5,250 ng/mL with automatic rerun</td><td>150 - 69,000 ng/mL with automatic rerun</td></tr><tr><td>Detection Limit</td><td>ACL Family: 140 ng/mL ACL Futura/ACL Advance: 156 ng/mL ACL TOP: 69 ng/mL</td><td>ACL TOP: 21 ng/mL</td></tr><tr><td>Within-run Precision (% CV)</td><td>ACL Family: 4.5% at 246 ng/mL</td><td>ACL TOP: •8.3% at 180 ng/mL</td></tr><tr><td rowspan="10"></td><td>•6.01% at 310 ng/mL</td><td>•3.7% at 314 ng/mL</td></tr><tr><td></td><td></td></tr><tr><td>• 2.42% at 732 ng/mL</td><td>•2.0% at 677 ng/mL</td></tr><tr><td>ACL Futura/ACL Advance:</td><td></td></tr><tr><td>• 11.82% at 304 ng/mL</td><td></td></tr><tr><td>3.59% at 813 ng/mL</td><td></td></tr><tr><td></td><td></td></tr><tr><td>ACL TOP:</td><td></td></tr><tr><td>6.8% at 282 ng/mL</td><td></td></tr><tr><td>4.6% at 340 ng/mL • 2.5% at 729 ng/mL</td><td></td></tr><tr><td>Interferences</td><td></td><td></td></tr><tr><td rowspan="6"></td><td>ACL Family, ACL Futura/ACL Advance Systems:</td><td>ACL TOP:</td></tr><tr><td>Hemoglobin up to 50 mg/dL</td><td>Hemoglobin up to 500 mg/dL</td></tr><tr><td>Bilirubin up to 5 mg/dL</td><td>Bilirubin up to 18 mg/dL</td></tr><tr><td>Lipids up to 1000 mg/dL</td><td>• Triglycerides up to 1327 mg/dL</td></tr><tr><td>Rheumatoid Factor up to 60 IU/mL ACL TOP</td><td>Rheumatoid Factor up to 1400 UI/mL</td></tr><tr><td>Hemoglobin up to 100 mg/dL Bilirubin up to 10 mg/dL Triglycerides up to 1500 mg/dL The presence of Rheumatoid Factor</td><td></td></tr><tr><td></td><td>may produce an overestimation of the test result</td><td></td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable): N/A

# L. Test Principle:

The assay is based on the decrease of the transmitted light caused by the aggregates which form when a patient plasma containing D-Dimer is mixed with latex particles coated with monoclonal antibody. The degree of agglutination is directly proportional to the concentration of D-Dimer in the sample.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance: extended claim, see original submission (K050278) for analytical studies.

a. Precision/Reproducibility: Additional precision study using a sample close to the cut-off:

<table><tr><td rowspan=1 colspan=1>Instrument</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Mean (ng/mL)</td><td rowspan=1 colspan=1>CV% (within-run)</td><td rowspan=1 colspan=1>CV% (Total)</td></tr><tr><td rowspan=1 colspan=1>ACLELITE PRO</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>4.5</td><td rowspan=1 colspan=1>11.7</td></tr><tr><td rowspan=1 colspan=1>ACL TOP</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>282</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>9.0</td></tr></table>

b. Linearity/assay reportable range:

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

d. Detection limit:

e. Analytical specificity:

f. Assay cut-off:

2. Comparison studies: extended claim, see original submission (K050278) for comparison studies

a. Method comparison with predicate device: b. Matrix comparison: N/A

3. Clinical studies:

a. Clinical Sensitivity:

HemosIL D-Dimer was used in a multi-center management study involving samples from patients admitted consecutively to the emergency unit with suspected DVT or PE using representative IL Coagulation Systems: ACL TOP and ACL ELITE instruments. The ACL TOP represents the linear analyzer group (ACL TOP, ACL Advance/Futura), the ACL ELITE represents the centrifugal group (ACL 8/9/10000/Elite/ElitePro, ACL 100- 7000 Series).

The Wells model was used to assess PTP (pre-test probability) score. The patients were classified as having a low, moderate, or high probability of DVT or PE.

Patients with a negative D-Dimer test result and a low PTP score underwent no further diagnostic testing and were followed-up after 3 months for development of DVT or PE. • For patients with a negative D-Dimer test result and a moderate PTP, it was the physician’s decision whether to follow-up after 3 months or to undergo imaging techniques. Data indicated that all patients with a negative D-Dimer test and a moderate PTP received either 3 months of follow-up, or imaging with 3 months of follow-up if the imaging result was negative. Patients with a positive D-Dimer test result or a high PTP score were imaged. Data indicated that all patients received 3 months of followup if the imaging result was negative. As of the 3 month follow-up, none of the patients that were negative through D-Dimer testing and imaging had developed DVT or PE. Through imaging techniques, one patient with a negative D-Dimer test result on the ACL ELITE and a moderate PTP score was confirmed for PE.

Previously established clinical cut-off of $2 3 0 ~ \mathrm { n g / m L }$ for HemosIL D-Dimer (K050278) was used for calculation. Statistical evaluation of the respective data sets from the four sites was performed using analysis of variance (ANOVA) to verify whether the three PE sites could be pooled and the three DVT sites could be pooled. The results were within acceptable limit $( \mathsf { p } { > } 0 . 0 5 )$ .

ACL TOP: 302 patients were suspected of DVT and 330 patients were suspected of PE.

DVT samples: Of the 302 total DVT suspected patients (175 females, 127 males). The overall prevalence of DVT in the total population of samples was $1 9 . 5 \%$ (59/302).   
PE samples: Of 330 total PE suspected patients (188 females, 142 males). The overall prevalence of PE in the total population of samples was $1 5 . 2 \%$ (50/330).

The sensitivity, specificity and negative predictive value (NPV) of HemosIL D-Dimer for DVT and PE is summarized below with the corresponding $9 5 \%$ confidence intervals (CI):

<table><tr><td rowspan=1 colspan=4>ACL TOP</td></tr><tr><td rowspan=1 colspan=1>DVT Performance</td><td rowspan=1 colspan=1>All samples</td><td rowspan=1 colspan=1>High PTP</td><td rowspan=1 colspan=1>Low + Moderate PTP</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>302</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>249</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>100.0% (59/59)(93.9%-100.0%)</td><td rowspan=1 colspan=1>100.0% (27/27)(87.2%-100.0%)</td><td rowspan=1 colspan=1>100.0% (32/32)(89.1%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>41.6% (101/243)(35.3%-48.0%)</td><td rowspan=1 colspan=1>34.6% (9/26)(17.2%-55.7%)</td><td rowspan=1 colspan=1>42.4% (92/217)(35.7%-49.3%)</td></tr><tr><td rowspan=1 colspan=1>Negative PredictiveValue</td><td rowspan=1 colspan=1>100.0% (101/101)(96.4%-100.0%)</td><td rowspan=1 colspan=1>100.0% (9/9)(66.4%-100.0%)</td><td rowspan=1 colspan=1>100.0% (92/92)(96.1%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Positive PredictiveValue</td><td rowspan=1 colspan=1>29.4% (59/201)(23.2%-36.2%)</td><td rowspan=1 colspan=1>61.4% (27/44)(45.5%-75.6%)</td><td rowspan=1 colspan=1>20.4% (32/157)(14.4%-27.5%)</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>19.5% (59/302)(15.2%-24.5%)</td><td rowspan=1 colspan=1>50.9% (27/53)(36.8%-64.9%)</td><td rowspan=1 colspan=1>12.9% (32/249)(9.0%-17.7%)</td></tr><tr><td rowspan=1 colspan=1>PE Performance</td><td rowspan=1 colspan=1>All samples</td><td rowspan=1 colspan=1>High PTP</td><td rowspan=1 colspan=1>Low + Moderate PTP</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>330</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>306</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>100.0% (50/50)(92.9%-100.0%)</td><td rowspan=1 colspan=1>100.0% (7/7)(59.0%-100.0%)</td><td rowspan=1 colspan=1>100.0% (43/43)(91.8%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>29.3% (82/280)(24.0%-35.0%)</td><td rowspan=1 colspan=1>17.6% (3/17)(3.8%-43.4%)</td><td rowspan=1 colspan=1>30.0% (79/263)(24.6%-36.0%)</td></tr><tr><td rowspan=1 colspan=1>NegativePredictive Value</td><td rowspan=1 colspan=1>100.0% (82/82)(95.6%-100.0%)</td><td rowspan=1 colspan=1>100.0% (3/3)(29.2%-100.0%)</td><td rowspan=1 colspan=1>100.0% (79/79)(95.4%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>PositivePredictive Value</td><td rowspan=1 colspan=1>20.2% (50/248)(15.4%-25.7%)</td><td rowspan=1 colspan=1>33.3% (7/21)(14.6%-57.0%)</td><td rowspan=1 colspan=1>18.9% (43/227)(14.1%-24.7%)</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>15.2% (50/330)(11.5%-19.5%)</td><td rowspan=1 colspan=1>29.2% (7/24)(12.6%-51.1%)</td><td rowspan=1 colspan=1>14.1% (43/306)(10.4%-18.5%)</td></tr></table>

ACL ELITE: 298 patients were suspected of DVT and 331 patients were suspected of PE.

DVT samples: Of the 298 total DVT suspected patients (173 females, 125 males). The overall prevalence of DVT in the total population of samples was $2 0 . 5 \%$ (61/298).   
PE samples: Of 331 total PE suspected patients (193 females, 138 males). The overall prevalence of PE in the total population of samples was $1 5 . 1 \%$ (50/331).

The sensitivity, specificity and negative predictive value (NPV) of HemosIL D-Dimer for DVT and PE is summarized below with the corresponding $9 5 \%$ confidence intervals (CI):

<table><tr><td rowspan=1 colspan=4>ACL ELITE</td></tr><tr><td rowspan=1 colspan=1>DVT Performance</td><td rowspan=1 colspan=1>All samples</td><td rowspan=1 colspan=1>High PTP</td><td rowspan=1 colspan=1>Low + Moderate PTP</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>298</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>244</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>100.0% (61/61)(94.1%-100.0%)</td><td rowspan=1 colspan=1>100.0% (29/29)(88.1%-100.0%)</td><td rowspan=1 colspan=1>100.0% (32/32)(89.1%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>33.8% (80/237)(27.8%-40.2%)</td><td rowspan=1 colspan=1>24.0% (6/25)(9.4%-45.1%)</td><td rowspan=1 colspan=1>34.9% (74/212)(28.5%-41.7%)</td></tr><tr><td rowspan=1 colspan=1>Negative PredictiveValue</td><td rowspan=1 colspan=1>100.0% (80/80)(95.5%-100.0%)</td><td rowspan=1 colspan=1>100.0% (6/6)(54.1%-100.0%)</td><td rowspan=1 colspan=1>100.0% (74/74)(95.1%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Positive PredictiveValue</td><td rowspan=1 colspan=1>28.0% (61/218)(22.1%-34.4%)</td><td rowspan=1 colspan=1>60.4% (29/48)(45.3%-74.2%)</td><td rowspan=1 colspan=1>18.8% (32/170)(13.2%-25.5%)</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>20.5% (61/298)(16.0%-25.5%)</td><td rowspan=1 colspan=1>53.7% (29/54)(39.6%-67.4%)</td><td rowspan=1 colspan=1>13.1% (32/244)(9.1%-18.0%)</td></tr><tr><td rowspan=1 colspan=1>PE Performance</td><td rowspan=1 colspan=1>All samples</td><td rowspan=1 colspan=1>High PTP</td><td rowspan=1 colspan=1>Low + ModeratePTP</td></tr><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>331</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>306</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>98.0% (49/50)(89.4%-99.9%)</td><td rowspan=1 colspan=1>100.0% (8/8)(63.1%-100.0%)</td><td rowspan=1 colspan=1>97.6% (41/42)(87.4%-99.9%)</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>41.3% (116/281)(35.5%-47.3%)</td><td rowspan=1 colspan=1>41.2% (7/17)(18.4%-67.1%)</td><td rowspan=1 colspan=1>41.3% (109/264)(35.3%-47.5%)</td></tr><tr><td rowspan=1 colspan=1>Negative PredictiveValue</td><td rowspan=1 colspan=1>99.1% (116/117)(95.3%-100.0%)</td><td rowspan=1 colspan=1>100.0% (7/7)(59.0%-100.0%)</td><td rowspan=1 colspan=1>99.1% (109/110)(95.0%-100.0%)</td></tr><tr><td rowspan=1 colspan=1>Positive PredictiveValue</td><td rowspan=1 colspan=1>22.9% (49/214)(17.4%-29.1%)</td><td rowspan=1 colspan=1>44.4% (8/18)(21.5%-69.2%)</td><td rowspan=1 colspan=1>20.9% (41/196)(15.4%-27.3%)</td></tr><tr><td rowspan=1 colspan=1>Prevalence</td><td rowspan=1 colspan=1>15.1% (50/331)(11.4%-19.4%)</td><td rowspan=1 colspan=1>32.0% (8/25)(14.9%-53.5%)</td><td rowspan=1 colspan=1>13.7% (42/306)(10.1%-18.1%)</td></tr></table>

$b$ . Clinical specificity: see above

4. Clinical cut-off: $2 3 0 ~ \mathrm { n g / m L }$ ; same as K050278

5. Expected values/Reference range: N/A

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

1. The submitted information in this premarket notification is complete and supports a substantial equivalence decision.